4.3 Article

The Management of Cognitive Impairment in Bipolar Disorder: Current Status and Perspectives

Journal

AMERICAN JOURNAL OF THERAPEUTICS
Volume 22, Issue 6, Pages 477-486

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MJT.0000000000000120

Keywords

bipolar disorder; cognitive impairment; neuropsychology; cognition

Funding

  1. Pat Rutherford, Jr Chair in Psychiatry at UTHealth
  2. Janssen
  3. Bristol-Myers Squibb
  4. Forest
  5. Merck
  6. Pfizer
  7. Abbott
  8. [1R01MH085667]

Ask authors/readers for more resources

Bipolar disorder (BD) is associated with important cognitive deficits that persist during the periods of remission. Although these deficits seem to play an important role in the functional impairment experienced by bipolar patients, evidence regarding their clinical management is scant. We revised the databases PubMed, MEDLINE, and clinicaltrials.gov, searching for studies focusing on the pharmacological and nonpharmacological treatment of cognitive deficits among bipolar patients. In addition, a manual search of bibliographical cross-references was performed. Currently, there is no Food and Drug Administration-approved pharmacological agent for the management of cognitive deficits in BD. A number of agents have been tested in the treatment of cognitive deficits in BD, with mixed results. Nonpharmacological interventions, such as cognitive remediation and noninvasive brain stimulation techniques, seem promising, but their role has not yet been properly explored among bipolar patients. Additional studies, aiming at evaluating the efficacy of interventions combining cognitive rehabilitation and biological treatments, are highly desirable.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Editorial Material Clinical Neurology

Mood and Affect in the COVID-19 Era COMMENT

Marsal Sanches

JOURNAL OF NERVOUS AND MENTAL DISEASE (2021)

Review Biochemistry & Molecular Biology

Deep brain stimulation of the medial forebrain bundle: a strategy to modulate the reward system and manage treatment-resistant depression

Albert J. Fenoy, Joao Quevedo, Jair C. Soares

Summary: In this article, the medial forebrain bundle and its importance in the modulation of affective disorders such as major depression is discussed. The role of the reward system in depression, particularly in anhedonia and lack of motivation, is emphasized. Recent trials have shown promising results in using deep brain stimulation (DBS) to alleviate depressive symptoms through modulation of this white matter pathway.

MOLECULAR PSYCHIATRY (2022)

Article Clinical Neurology

Correlations between peripheral levels of inflammatory mediators and frontolimbic structures in bipolar disorder: an exploratory analysis

Satyajit Mohite, Haitham Salem, Thiago Cordeiro, Jonika Tannous, Benson Mwangi, Sudhakar Selvaraj, Jair C. Soares, Marsal Sanches, Antonio L. Teixeira

Summary: This study found that euthymic patients with bipolar disorder have lower volumes in certain brain regions compared to healthy controls, with negative correlation between interferon-gamma levels and right medial-orbitofrontal volume, and positive correlation between interleukin-10 levels and left posterior cingulate volume, suggesting the involvement of inflammatory pathways in structural brain changes in bipolar disorder.

CNS SPECTRUMS (2022)

Article Clinical Neurology

Investigation of endophenotype potential of decreased fractional anisotropy in pediatric bipolar disorder patients and unrelated offspring of bipolar disorder patients

Mehmet A. Camkurt, Tomas Melicher, Benson Mwangi, Mon-Ju Wu, Bo Cao, Cristian P. Zeni, Jonika Tannous, Giovana Zunta-Soares, Khader Hasan, Marsal Sanches, Jair C. Soares

Summary: This study found significantly decreased fractional anisotropy (FA) in six brain areas of offspring of patients with BD, suggesting a potential endophenotype for BD. In contrast, FA values in three regions were increased in controls, indicating differences in brain structure between the groups.

CNS SPECTRUMS (2022)

Article Psychiatry

Treatment-resistant bipolar depression: concepts and challenges for novel interventions

Alexandre P. Diaz, Brisa S. Fernandes, Joao Quevedo, Marsal Sanches, Jair C. Soares

Summary: Treatment-resistant bipolar depression (TRBD) is common in patients with bipolar disorders, but there are limited interventions. This review identified promising new interventions for TRBD, including both pharmacological and non-pharmacological treatments. More research is needed to personalize current treatments.

BRAZILIAN JOURNAL OF PSYCHIATRY (2022)

Article Biochemistry & Molecular Biology

Dysregulation of mitochondrial dynamics, mitophagy and apoptosis in major depressive disorder: Does inflammation play a role?

Giselli Scaini, Brittany L. Mason, Alexandre P. Diaz, Manish K. Jha, Jair C. Soares, Madhukar H. Trivedi, Joao Quevedo

Summary: Recent studies have shown that mitochondrial dysfunction and dysregulated neuroinflammatory pathways play a role in major depressive disorder (MDD). This study found differences in markers of mitochondrial dynamics, mitophagy, autophagy, and apoptosis in MDD patients compared to healthy controls, with higher levels of specific proteins associated with mitochondrial dysfunction in MDD patients. Furthermore, inflammation and protein levels related to mitochondrial dynamics and mitophagy were found to influence the severity of depressive symptoms in MDD patients.

MOLECULAR PSYCHIATRY (2022)

Review Biochemistry & Molecular Biology

Alterations in brain synaptic proteins and mRNAs in mood disorders: a systematic review and meta-analysis of postmortem brain studies

Edison Leung, Ethan W. Lau, Andi Liang, Constanza de Dios, Robert Suchting, Linda Ostlundh, Joseph C. Masdeu, Masahiro Fujita, Marsal Sanches, Jair C. Soares, Sudhakar Selvaraj

Summary: This study systematically reviews the pathophysiological mechanisms of bipolar and major depressive disorders, focusing on synaptic proteins and RNA alterations. Meta-analysis results indicate specific changes in synaptic proteins and RNAs in both disorders, although conflicting results are observed due to small sample sizes and variations in data sources.

MOLECULAR PSYCHIATRY (2022)

Article Biochemistry & Molecular Biology

Deep brain stimulation of the medial forebrain bundle: sustained efficacy of antidepressant effect over years

Albert J. Fenoy, Paul E. Schulz, Marsal Sanches, Sudhakar Selvaraj, Christina L. Burrows, Bashar Asir, Christopher R. Conner, Joao Quevedo, Jair C. Soares

Summary: This study demonstrates that deep brain stimulation to the superolateral branch of the medial forebrain bundle is an effective therapy for treatment resistant depression, with sustained antidepressant effects observed for up to 5 years. Evaluation of modulated fiber tracts reveals significant prefrontal/orbitofrontal connectivity to the target region in all responders.

MOLECULAR PSYCHIATRY (2022)

Article Biochemistry & Molecular Biology

Brain metabolic changes and clinical response to superolateral medial forebrain bundle deep brain stimulation for treatment-resistant depression

Christopher R. Conner, Joao Quevedo, Jair C. Soares, Albert J. Fenoy

Summary: This study used PET imaging to observe brain metabolic changes in patients with treatment-resistant depression who underwent deep brain stimulation (DBS). The results showed significant decreases in metabolism in the bilateral caudate, mediodorsal thalamus, and dorsal anterior cingulate cortex at 6 to 12 months post-surgery, as well as a decrease in the left ventral prefrontal cortex at 12 months post-surgery. These metabolic changes were correlated with clinical response.

MOLECULAR PSYCHIATRY (2022)

Letter Biochemistry & Molecular Biology

Discontinuation of deep brain stimulation to the medial forebrain bundle leads to depression relapse: considerations when reinstating stimulation

Albert J. Fenoy, Joao Quevedo, Jair C. Soares

MOLECULAR PSYCHIATRY (2023)

Article Biochemistry & Molecular Biology

Mitochondrial health index correlates with plasma circulating cell-free mitochondrial DNA in bipolar disorder

Rafaela C. Cordeiro, Camila N. C. Lima, Gabriel R. Fries, Giovana Zunta-Soares, Jair C. Soares, Joao Quevedo, Giselli Scaini

Summary: This study investigates the impact of mitochondrial dysfunction on bipolar disorder (BD). The study finds that BD patients have a lower mitochondrial health index (MHI) compared to non-psychiatry controls, with a negative correlation between MHI and cell-free mtDNA levels. The study further reveals that MHI is related to the expression of mitochondria quality control (MQC) proteins, and a longer illness duration, worse functional status, and higher depressive symptoms are associated with lower MHI and higher cell-free mtDNA levels.

MOLECULAR PSYCHIATRY (2023)

Article Psychology, Multidisciplinary

The Limits between Schizophrenia and Bipolar Disorder: What Do Magnetic Resonance Findings Tell Us?

Mirona Letitia Dobri, Alexandre Paim Diaz, Sudhakar Selvaraj, Joao Quevedo, Consuelo Walss-Bass, Jair C. Soares, Marsal Sanches

Summary: Schizophrenia and bipolar disorder share many similarities in terms of their premorbid course, clinical profile, genetic factors and treatment approaches. Neuroimaging studies show that they both involve structural changes and functional dysconnectivity in critical brain regions, suggesting a continuum between these two disorders.

BEHAVIORAL SCIENCES (2022)

No Data Available